This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/molecular-hydrogen-and-redox-signaling-in-ocular-neuroprotection

Test your visual field online: https://visualfieldtest.com

Excerpt:

Introduction Eye diseases like glaucoma, diabetic retinopathy and age-related macular degeneration share a common culprit: oxidative stress from harmful reactive oxygen species (ROS). Excess ROS can damage DNA, lipids and proteins in the retina and optic nerve, driving vision loss () (). Molecular hydrogen (H₂) has emerged as a unique antioxidant therapy. H₂ is a tiny, tasteless gas that easily penetrates cell membranes and ocular barriers (). It selectively neutralizes only the most toxic ROS (like hydroxyl radicals •OH and peroxynitrite ONOO⁻) while leaving normal signaling ROS intact (). In doing so, H₂ restores cellular redox balance without blocking beneficial biochemical signals. In addition, H₂ can trigger protective pathways – for example, it upregulates antioxidant enzymes (superoxide dismutase, catalase, glutathione systems) via Nrf2 signaling and suppresses pro-inflammatory factors () (). These properties suggest H₂ could guard retinal neurons (and the optic nerve) by modulating redox signaling in ophthalmic tissues. Mechanisms of H₂ Action in Ocular Tissues The therapeutic appeal of H₂ lies in its physical properties. As the smallest molecule, it diffuses rapidly through tissues and bio-barriers (). For example, inhaled H₂ or hydrogen-saturated water (HRW) quickly elevates H₂ levels in the blood and eyes. Once inside cells, H₂ “soaks up” highly reactive radicals. Unlike general antioxidants, H₂ does not indiscriminately scavenge all ROS – it reacts preferentially with the strongest oxidants (). This means normal ROS signaling (needed for cell function) is preserved while damaging radicals are detoxified. In practice, studies show H₂ lowers oxidative biomarkers (like 4-hydroxynonenal and malondialdehyde) and inflammatory mediators in ocular cells and tissues. Importantly, H₂ also modulates signaling pathways. It has been shown to activate the master antioxidant regulator Nrf2 (boosting cellular defenses) and inhibit inflammatory cascades (for example suppressing NF-κB and pro-inflammatory cytokines) () (). In the eye, this translates to reduced microglial activation and cell death after injury () (). In short, H₂ acts as a gentle, “tunable” antioxidant that changes the redox environment and gene expression in a protective direction. Experimental Ocular Neuroprotection A growing body of animal research supports H₂’s neuroprotective role in the eye. In rodent glaucoma models (e.g. acute intraocular pressure spikes), H₂ treatment consistently preserved retinal neurons. For instance, one study gave rats continuous H₂-enriched eye drops during pressure-induced ischemia, and found the vitreous H₂ level rose quickly. This intervention suppressed I/R-induced oxidative stress and sharply reduced retinal ganglion cell (RGC) apoptosis (). Similarly, intraperitoneal injection of hydrogen-rich saline (HRS) in rats limited retinal DNA oxidation and blunted over-activation of PARP-1 (a DNA repair enzyme that can trigger cell death). As a result, fewer RGCs died after injury (). In another experiment, inhaling H₂ gas for one hour daily (7 days) significantly lessened RGC loss in a rat retinal ischemia-reperfusion model (). Notably, measured inflammatory mediators (IL-1β, TNF-α) and oxidative byproducts (4-HNE) were much lower in H₂-treated eyes (). These findings highlight that H₂ can mitigate the oxidative and inflammatory cascades underlying glaucomatous n

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/anthocyanins-and-bilberry-extracts-retinal-resilience-and-aging-microvasculature

Test your visual field online: https://visualfieldtest.com

Excerpt:

Anthocyanins and Bilberry Extracts: Retinal Resilience and Aging MicrovasculatureThe flavonoids anthocyanins (pigments in berries) have long been claimed to benefit eye health, and modern studies suggest they do concentrate in ocular and vascular tissues (). These compounds are powerful antioxidants and anti‐inflammatory agents: they scavenge free radicals, stabilize blood vessel walls, and even inhibit platelet aggregation and inflammatory mediators (). In the retina – a high‐metabolism organ especially vulnerable to oxidative stress – anthocyanins from bilberry (Vaccinium myrtillus) may bolster the defense against aging and disease. Antioxidant and Anti‐Inflammatory Effects in the RetinaAnimal research confirms that bilberry anthocyanins protect retinal cells by enhancing antioxidant systems and damping inflammation. In a rabbit model of light‐induced retinal damage, oral bilberry extract (high in anthocyanins) preserved retinal function and structure. Treated rabbits showed higher levels of antioxidant enzymes (superoxide dismutase, glutathione peroxidase, catalase) and total antioxidant capacity than controls, along with lower malondialdehyde (a marker of lipid oxidation) (). At the same time, pro‐inflammatory and angiogenic signals such as interleukin‐1β and VEGF were suppressed (). These changes indicate that bilberry anthocyanins can neutralize excess reactive oxygen species (ROS) in the retina and prevent the downstream inflammation that would otherwise damage retinal cells. In a mouse model of retinal inflammation (endotoxin‐induced uveitis), anthocyanin‐rich bilberry extract preserved photoreceptor health. Treated mice had better electroretinogram (ERG) responses (reflecting photoreceptor function) and intact photoreceptor outer segments compared to untreated mice. This protective effect was linked to blockade of inflammatory signaling (specifically, bilberry suppressed IL-6/STAT3 activation) and reduction of ROS‐driven NF-κB activation (). In short, bilberry anthocyanins curtailed the molecular cascade of inflammation and oxidative stress that would otherwise impair vision. Retinal ganglion cells (RGCs) – the neurons whose axons form the optic nerve – also appear to benefit from anthocyanins. In a mouse optic nerve‐crush model (mimicking glaucoma‐like injury), oral bilberry extract dramatically increased RGC survival. This neuroprotective effect was accompanied by upregulation of endoplasmic‐reticulum chaperones (Grp78 and Grp94) around the RGC layer and a decrease in stress/apoptosis genes (Chop, Bax, Atf4) (). In other words, anthocyanins helped activated cellular “stress machines” that prevent cell death under injury. These experimental results suggest bilberry anthocyanins can support RGC resilience in situations of oxidative or ER stress (as in glaucoma), likely through antioxidant and anti‐apoptotic pathways ().Vascular Effects on the Optic Nerve Head and Peripapillary RetinaBeyond direct neural protection, anthocyanins may improve ocular microcirculation, especially around the optic nerve (peripapillary region). In patients with normal‐tension glaucoma (NTG), daily supplementation with a standardized bilberry anthocyanin extract (50 mg of total anthocyanins per day) for six months significantly increased blood flow in the optic nerve head and peripapillary retina, measured by laser Doppler flowmetry (). In that study,

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/taurine-and-retinal-ganglion-cell-survival-across-the-lifespan

Test your visual field online: https://visualfieldtest.com

Excerpt:

IntroductionTaurine is a nutrient-rich amino sulfonic acid found in high concentrations in the retina and other neural tissues. In fact, taurine levels in the retina are higher than in any other body tissue, and its depletion causes retinal cell damage (). Adequate taurine is known to be essential for retinal neurons, especially the photoreceptors and retinal ganglion cells (RGCs). RGC degeneration underlies vision loss in glaucoma and other optic neuropathies. Preclinical research now suggests that taurine can help maintain RGC health. This article reviews how taurine regulates cell volume and calcium to protect RGCs, the evidence from laboratory models that taurine promotes RGC survival, and the limited clinical data hinting at vision benefits. We also discuss how diet and aging affect taurine levels, related health outcomes, and what is known about safe taurine supplementation and priorities for future trials.Taurine in the Retina: Osmoregulation and Calcium HomeostasisTaurine plays key cellular roles beyond being a nutrient. In the retina it acts as an organic osmolyte, helping cells adjust their volume under stress. Retinal cells (including RPE, RGCs, and Müller glia) express the taurine transporter (TauT) to import taurine. Under hyperosmotic stress (such as high salt or sugar conditions), TauT expression and activity increase, causing cells to uptake more taurine and water. This protects retinal cells from shrinkage or swelling () (). In other tissues (like brain astrocytes) taurine effluxes out in hypotonic conditions, allowing cells to maintain osmotic balance. Thus, taurine is fundamental to osmoregulation in the retina, buffering RGCs against fluid stress that can occur in diabetes or infarction () ().Taurine also helps regulate intracellular calcium (Ca2+), a critical factor in neuron survival. Excess cytosolic Ca2+ can trigger mitochondrial damage and cell death. Taurine influences calcium by several mechanisms. In RGCs and other neurons, taurine has been shown to increase the capacity of mitochondria to sequester Ca2+, thereby lowering harmful free cytosolic Ca2+ (). It also modulates calcium influx through voltage-gated Ca2+ and sodium channels, acting somewhat like a natural calcium channel regulator (). By reducing intracellular calcium spikes, taurine prevents the opening of mitochondrial permeability pores and the apoptotic cascades they can trigger (). In short, taurine helps keep RGC calcium homeostasis in check, which in turn protects mitochondria and prevents calcium-driven injury () ().Oxidative Stress and NeuroprotectionBeyond osmoregulation and calcium, taurine is a potent antioxidant and neuroprotectant. It can directly scavenge reactive molecules such as hypochlorous acid, and it helps preserve the activity of key antioxidant enzymes. In retinal models, taurine supplementation boosts glutathione levels and enzymes like superoxide dismutase and catalase () (). By reducing oxidative stress, taurine helps prevent the oxidative damage that is a major cause of retinal degeneration. Taurine has also been linked to anti-apoptotic pathways: it tends to down-regulate pro-death proteins and up-regulate survival proteins in neurons () (). For example, in CNS cells taurine inhibits caspases and calpains (enzymes involved in apoptosis) and maintains a healthy balance of Bcl-2 family proteins ().

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/green-tea-catechins-egcg-for-neurovascular-health-in-glaucoma-and-aging

Test your visual field online: https://visualfieldtest.com

Excerpt:

EGCG and Neurovascular Health in Glaucoma and AgingGreen tea cultures have long prized their tea’s catechins—particularly epigallocatechin-3-gallate (EGCG)—for promoting health. Modern research suggests EGCG’s potent antioxidant, anti-inflammatory and vasodilatory effects might benefit the neurovascular system in glaucoma and aging. In glaucoma, retinal ganglion cells (RGCs) degenerate under stress, and intraocular pressure (IOP) rises due to trabecular meshwork (TM) dysfunction. We review animal and cell studies of EGCG on RGC survival, TM extracellular matrix (MMPs) and blood flow, then summarize limited human data on vision and ocular structure. We connect these to EGCG’s known effects on cardiovascular and cognitive aging, and discuss its bioavailability, caffeine content, and safety.Retinal Ganglion Cell Protection (Preclinical)Preclinical studies consistently show EGCG helps RGC survival after injury or elevated IOP. In a mouse glaucoma model (microbead-induced high IOP), oral EGCG (50 mg/kg·d) preserved RGC density: treated mice had significantly more fluorogold-labeled RGCs versus untreated controls (). In rats with acute IOP elevation, EGCG treatment markedly reduced optic nerve damage and inflammatory cytokines. For example, in one study EGCG lowered IL-6, TNF-α and other inflammatory signals, and inhibited NF-κB activation, thereby attenuating glaucoma symptoms and RGC injury (). These neuroprotective effects likely derive from EGCG’s ability to quench free radicals and block stress pathways (e.g. activating Nrf2/HO-1 in ischemia models ()). In cell culture, EGCG blocked oxidative and ultraviolet stress in RGC lines. Thus, multiple lines of evidence indicate that EGCG can mitigate RGC degeneration in animal glaucoma or optic nerve injury models (often via anti-oxidant and anti-inflammatory mechanisms) () (). Trabecular Meshwork and Aqueous OutflowMMPs (matrix metalloproteinases) regulate the extracellular matrix of the TM and thus aqueous outflow and IOP. Adequate MMP activity “elevates aqueous outflow, reducing IOP,” whereas reduced MMPs increase outflow resistance (). EGCG and other catechins are known MMP modulators. For instance, catechin treatment can suppress MMP-9 expression in humans (e.g. lowering MMP-9 in hypertension) (). In ocular models, EGCG has anti-fibrotic and cell-protective effects on TM cells. Zhou et al. found 40 μM EGCG dramatically improved human and porcine TM cell survival under ER stress: EGCG curtailed stress markers (ATF4, HSPA5, DDIT3) by ~50-70% and rescued cell viability () (). By reducing TM cell dysfunction, EGCG pretreatment may help maintain normal outflow. Similarly, EGCG strongly inhibited TGF-β1–induced fibrotic changes in human Tenon’s fibroblasts: treated cells showed dramatically lower α-smooth muscle actin and collagen expression (). This suggests EGCG can blunt ECM deposition, which in TM would preserve lumen. In sum, preclinical data imply EGCG’s anti-oxidant/anti-fibrotic actions protect TM cells and could facilitate aqueous clearance, complementing its IOP-lowering potential () ().Ocular Perfusion and Vascular EffectsEGCG has vasoactive properties that may boost ocular perfusion. Mechanistically, EGCG activates endothelial nitric oxide synthase (eNOS) and increases nitric oxide (NO) production via PI3K/Akt pathways (). This causes vasodilation and improved microcirculation. In the retina, enhanced NO-mediated blo

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/melatonin-circadian-rhythms-and-nocturnal-iop-dynamics

Test your visual field online: https://visualfieldtest.com

Excerpt:

Melatonin and the Eye: Nighttime IOP and NeuroprotectionMelatonin is a neurohormone produced in a ~24-hour cycle (circadian rhythm) that plays key roles in sleep regulation and acts as a powerful antioxidant. In the eye, melatonin is synthesized locally (in the retina and ciliary body) and binds to MT1/MT2 melatonin receptors on ocular cells (). Its levels peak at night, coinciding with the normal drop in blood pressure and (in healthy individuals) the typical reduction in intraocular pressure (IOP) during sleep. These circadian patterns mean melatonin helps modulate aqueous humor (the watery fluid filling the front of the eye) dynamics. In turn, this affects nighttime IOP and retinal health, especially in aging. Recent studies suggest that impaired melatonin signaling may contribute to glaucoma risk, while melatonin analogs (drugs that mimic melatonin) show promise in lowering IOP and protecting retinal neurons () ().Ocular Melatonin and Circadian ControlMelatonin is not only made by the pineal gland but also produced in the eye itself. Photoreceptors in the retina generate melatonin at night, and the ciliary body (the gland that produces aqueous humor) also synthesizes melatonin and releases it into the aqueous () (). This means melatonin levels in the aqueous humor rise in darkness, peaking around midnight to 2–4 AM (). By contrast, light exposure (especially blue light) suppresses melatonin via melanopsin-containing retinal ganglion cells. Thus, melatonin is a bridge between circadian signals (day–night) and intraocular physiology. Receptors for melatonin (MT1, MT2 and possibly MT3) are found on cells of the eye, including the non-pigmented ciliary epithelial cells that secrete aqueous humor (). Activation of these receptors influences cellular pathways (via G-proteins) that control ion transport and fluid secretion. In simple terms, melatonin engagement tends to slow aqueous humor production, helping lower IOP. Conversely, loss of normal melatonin signaling (as may happen in glaucoma or with aging) can lead to higher nighttime IOP. For example, mice lacking the MT1 receptor have higher nocturnal IOP and suffer more retinal ganglion cell (RGC) loss () (). Similarly, human glaucoma patients often secrete abnormally timed melatonin due to damage of light-sensitive retinal cells, suggesting a chicken-and-egg problem: glaucoma may disturb circadian rhythms, and disrupted melatonin may worsen glaucoma () ().Melatonin in Aqueous Humor DynamicsThe generation and drainage of aqueous humor set eye pressure. Melatonin influences both sides of this balance. As noted, melatonin slows aqueous production by ciliary epithelial cells via MT1/MT2 receptor signaling (which lowers cAMP inside the cells) () (). Experiments in animals show melatonin analogs reduce IOP dramatically. For instance, the MT3 agonist 5-MCA-NAT produced a 43% IOP drop in rabbits (versus 24% by melatonin itself) (). In glaucoma-model monkeys, 5-MCA-NAT lowered IOP steadily over days, with effects lasting >18 hours (). Similarly, the MT2 agonist IIK7 and other analogs have shown significant pressure-lowering in animals. This suggests multiple melatonin receptors (especially MT3) mediate IOP control () (). In addition to reducing production, melatonin may help increase aqueous outflow. It modulates ion channels (e.g. chloride transport) and enzymes in the ciliary body. One study found melatonin boosted Cl⁻ transport in po

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/the-gut-eye-axis-probiotics-metabolites-and-intraocular-pressure

Test your visual field online: https://visualfieldtest.com

Excerpt:

The Gut–Eye Axis and Ocular HealthThe emerging concept of a gut–eye axis recognizes that gut microbes and their products can affect the eye. Gut bacteria ferment fibers to produce short-chain fatty acids (SCFAs) (like acetate, propionate, butyrate) and modify bile acids (BAs). These metabolites enter the circulation and can reach the eye, influencing its immune environment and function (). For example, microbial dysbiosis – an imbalance in gut flora – has been linked to ocular diseases from age-related macular degeneration and uveitis to dry eye and glaucoma (). In fact, a recent survey found that gut imbalance is associated with multiple eye conditions, and only a handful of early trials (four of 25 studies) have tested interventions like probiotics or fecal transplants on eye disease (). This gut–eye axis suggests that gut-derived SCFAs, BAs, and even inflammatory components (like LPS) could modulate ocular immune tone (the baseline immune status) and affect tissues like the trabecular meshwork (the fluid drainage filter) and intraocular pressure (IOP).Microbial Metabolites and Ocular ImmunityShort-Chain Fatty Acids (SCFAs)SCFAs are fatty acids with fewer than six carbon atoms, mainly acetate, propionate, and butyrate, produced by gut bacteria digesting fiber. They regulate immune responses systemically () (). In the eye, SCFAs exert anti-inflammatory effects. In mouse models, injected SCFAs were detected in ocular tissues and reduced inflammation from endotoxin (LPS) exposure () (). This shows SCFAs can cross the blood–eye barrier via blood and calm intraocular inflammation. For instance, intraperitoneal butyrate in mice dampened LPS-induced uveitis, reducing pro-inflammatory cytokines and boosting regulatory T cells () (). Likewise, a review notes SCFAs attenuate ocular inflammation after systemic injection (). These anti-inflammatory actions imply SCFAs help maintain a healthy ocular immune tone (keeping immune activity in check). In contrast, gut-derived pro-inflammatory signals can harm the eye. Gut bacteria (especially Gram-negative) release LPS which triggers innate immune receptors like TLR4. TLR4 signaling is known to affect the trabecular meshwork and has been genetically linked to primary open-angle glaucoma (). In animals, giving LPS worsens retinal neuronal loss and photoreceptor damage (). Thus, a balanced gut flora (with abundant SCFA-producers) supports eye health, while dysbiosis may flood the eye with inflammatory signals.Bile AcidsBile acids (BAs) are cholesterol-derived compounds made by the liver and modified by gut microbes. Aside from digesting fats, BAs are signaling molecules with anti-inflammatory and neuroprotective roles (). Emerging evidence highlights BAs’ benefits in retinal and ocular disorders. For example, ursodeoxycholic acid (UDCA) and its taurine-conjugate TUDCA have shown protective effects in diabetic retinopathy and macular degeneration models (). In mouse diabetic retinopathy models, UDCA treatment restored the blood-retinal barrier and sharply reduced retinal inflammation (lowering IL-1β, IL-6) (). UDCA also preserved capillary integrity and reduced cell loss in the retina (). Moreover, systemic UDCA or TUDCA suppressed aberrant blood vessel growth (choroidal neovascularization) in ocular injury models (). Mechanistically, BAs act via receptors like FXR and TGR5. In experimental uveitis, low BA levels were found, and restoring BAs (throug

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/magnesium-for-vascular-dysregulation-in-glaucoma-and-aging-circulation

Test your visual field online: https://visualfieldtest.com

Excerpt:

Magnesium and Vascular Dysregulation in GlaucomaGlaucoma is a progressive optic nerve disease that leads to vision loss. While high intraocular pressure (IOP) is the best-known risk factor, many patients – especially those with normal-tension glaucoma (NTG) – develop glaucoma despite normal IOP (). In NTG, systemic vascular issues are believed to contribute: unstable blood flow, vasospasm (sudden vessel constriction), and excessive nighttime blood pressure dips can reduce blood supply to the optic nerve () (). Treatments that stabilize blood flow are therefore of interest in NTG. Magnesium, an essential mineral and natural calcium-channel blocker, has emerged as a candidate because it promotes vasodilation and nerve protection ().Magnesium’s Vascular ActionsMagnesium influences blood vessels and endothelial function in several ways:Calcium antagonism. Magnesium acts as a physiologic calcium channel blocker. It competes with calcium in muscle and blood vessels, causing smooth muscle relaxation and vasodilation. () In laboratory studies, raising Mg²⁺ levels inhibits endothelin-1–induced vessel constriction (for example, in porcine ciliary arteries) (). Because endothelin-1 is a powerful vasoconstrictor implicated in glaucoma, magnesium’s blockade of this pathway can improve perfusion. () Endothelial function. Healthy blood vessels produce relaxing factors like nitric oxide (NO). Magnesium enhances endothelial cell health and NO availability, leading to better blood flow. () Studies in coronary artery disease show that oral magnesium improves endothelium-dependent vasodilation (). By improving the balance of endothelin-1 vs. nitric oxide, magnesium can reduce abnormal vasoconstriction and oxidative stress in tiny ocular vessels. Vasospasm relief. Clinically, many NTG patients have Raynaud-like vasospasm (cold-triggered digital or nailfold spasms). In one pilot study of 10 glaucoma patients with cold-induced fingertip vasospasm, giving 121.5 mg magnesium twice daily for one month significantly improved peripheral capillary flow and digital temperature, and visual fields tended to improve (). This suggests magnesium can relieve systemic vasospasm, potentially stabilizing ocular perfusion (). Magnesium also has neuroprotective effects. By blocking NMDA receptors and inhibiting excitotoxic glutamate release, Mg²⁺ guards against retinal ganglion cell damage (). It stabilizes neuronal metabolism (supporting ATP production and antioxidants) (). In summary, magnesium helps normalize blood vessel tone and protect nerve cells – both relevant in glaucoma-related vascular dysregulation () ().Blood Pressure Dipping and Ocular PerfusionHealthy individuals have a 10–20% drop in blood pressure during sleep. Some glaucoma patients, especially NTG, experience excessive overnight dips or total hypotension, harming optic nerve perfusion. A landmark longitudinal study found that NTG patients whose mean arterial pressure stayed ≥10 mmHg below daytime levels for longer during sleep were much more likely to experience progressive visual field loss (). In other words, nocturnal hypotension (deep nighttime dips) predicted glaucomatous progression ().Magnesium status appears to influence this blood pressure rhythm. Low magnesium labs are linked to a non-dipping pattern – where nighttime BP fails to decline normally (). In hypertensive patients, hypomagnesemia blunted the normal

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/resveratrol-and-sirtuin-pathways-from-trabecular-meshwork-to-longevity

Test your visual field online: https://visualfieldtest.com

Excerpt:

Resveratrol’s Promise in Glaucoma: Ocular Cells and Systemic AgingResveratrol is a polyphenolic compound often touted as a “caloric restriction mimetic” and SIRT1 activator with antioxidant and anti-inflammatory effects. Early studies showed resveratrol can boost stress resistance and extend lifespan in organisms from yeast to mammals (). In cells and animal models, resveratrol activates SIRT1 – a deacetylase linked to longevity – which in turn induces autophagy (cellular cleanup) required for its healthspan benefits (). These same pathways – reduced oxidative stress, enhanced cellular renewal – underlie interest in resveratrol for age-related eye diseases. In glaucoma, where trabecular meshwork (TM) cells and retinal ganglion cells (RGCs) suffer chronic stress and senescence, resveratrol’s anti-aging mechanisms are being explored.Trabecular Meshwork: Fighting Senescence and StressThe TM tissue acts as the eye’s drainage filter and becomes less cellular and more dysfunctional in glaucoma. Chronic oxidative stress and inflammation in TM cells trigger senescence (marked by SA-β-gal, lipofuscin) and cytokine release (IL-1α, IL-6, IL-8, ELAM-1). In cultured TM cells subjected to high oxygen stress, chronic resveratrol (25 µM) virtually abolished the rise in reactive oxygen species (ROS) and inflammatory markers, and sharply reduced senescence markers (). In one study, resveratrol-treated TM cells had much lower SA-β-gal activity and protein carbonylation despite oxidative challenge (). This suggests resveratrol may preserve TM cell health by blocking stress-induced aging. Resveratrol also influences Nitric Oxide (NO) pathways in TM cells. In glaucomatous human TM cells, resveratrol increased endothelial NO synthase (eNOS) expression and boosted NO levels, while lowering inducible NOS (iNOS) at higher doses (). Since NO promotes blood flow and may reduce outflow resistance, increased NO could improve ocular perfusion and outflow facility. Likewise, lowering iNOS (which drives damaging oxidative stress) underscores resveratrol’s antioxidant role (). These effects align with its anti-inflammatory action: resveratrol downregulates pro-inflammatory IL-1α and related cytokines in TM cells ().Resveratrol’s benefits may also extend to autophagy in TM cells. Although specific ocular data are scarce, resveratrol is known to promote autophagy via SIRT1 in many cell types (). Autophagy is the process that clears damaged proteins and organelles, and it typically declines with age. Inducing autophagy could help TM cells dispose of stress-damaged components and maintain outflow function. In summary, preclinical TM data indicate resveratrol buffers TM cells against chronic stress and aging () ().Retinal Ganglion Cells: Neuroprotection and SIRT1Glaucomatous loss of RGCs leads to vision loss, and protecting these neurons is a key goal. In multiple rodent and cell studies, resveratrol has consistently shown neuroprotective effects on RGCs. It promotes RGC survival under stress by antioxidant and anti-apoptotic mechanisms (). For example, in cultured RGCs exposed to hydrogen peroxide (H₂O₂), resveratrol stimulated cell survival and growth, reduced apoptotic signaling, and lowered ROS levels (). It also blocked hypoxia-induced RGC death by suppressing pro-death pathways (e.g. diminishing ErbB2 protein) (). These actions are mediated in part via SIRT1: resveratrol prevents ph

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/macular-carotenoids-lutein-zeaxanthin-meso-zeaxanthin-beyond-the-macula

Test your visual field online: https://visualfieldtest.com

Excerpt:

Macular Carotenoids (Lutein, Zeaxanthin, Meso-zeaxanthin) Beyond the MaculaIntroduction: Lutein, zeaxanthin and meso-zeaxanthin are yellow-carotenoid pigments concentrated in the macula of the eye. Beyond filtering blue light in the retina, these macular carotenoids may affect visual and neural function more broadly – with potential relevance for glaucoma and aging. In glaucoma, early damage to retinal ganglion cells and their fibers impairs visual tasks like low-contrast and glare vision. Recent research has therefore explored whether boosting macular pigment (through diet or supplements) can improve contrast sensitivity, speed recovery from glare (photostress), and even neural processing efficiency. At the same time, lutein/zeaxanthin’s antioxidant and anti-inflammatory actions could protect retinal neurons and optic nerve tissue. We review the evidence linking these carotenoids to glaucoma-relevant vision metrics, to cellular stress in retina/nerve, and to broader benefits in aging – including cognition and cardiovascular health. Finally, we cover their absorption (bioavailability), dietary sources vs supplements, and safety profile.Carotenoids and Visual FunctionMacular carotenoids act as optical filters and antioxidants in the eye. By absorbing short-wavelength light and scavenging reactive oxygen species (ROS), they can improve visual performance. For example, higher macular pigment is known to improve contrast sensitivity and reduce glare in healthy eyes (). This occurs because dense pigment filters stray blue light, reducing intraocular scatter and enhancing the contrast of images on the retina. In one recent study, higher macular pigment density significantly improved contrast acuity and shortened recovery after a bright flash (photostress) (). In a one-year trial of healthy adults, daily lutein (10 mg) plus zeaxanthin (2 mg) raised macular pigment and speeded recovery from glare: subjects cleared a bright light exposure faster and showed better color contrast compared to placebo (). (In that study, reported glare disability also tracked pigment density, although supplementation did not produce a statistically significant change in glare threshold ().)In glaucoma specifically, patients often have reduced contrast sensitivity even before visual field loss is obvious. Macular lesions in glaucoma tend to spare central vision at first, but global visual quality suffers. It is plausible that enhancing macular pigment could help these patients tolerate glare or detect contrast better. Indeed, macular pigment’s filtering of blue light tends to improve contrast and diminish glare effects (). One glaucoma study noted that macular pigment improved “contrast sensitivity and glare disability” in healthy subjects, though its benefit in glaucoma (“glare disability in glaucoma”) may vary with lighting conditions (). Overall, data suggest that boosting lutein+zeaxanthin often leads to modest gains in real-world visual tasks. For example, in a large trial healthy subjects gained a significant advantage in color contrast tasks after one year of L/Z supplementation (). These visual gains support the idea that improved glare recovery and contrast could be achieved in any visual system, including in glaucoma patients.Beyond basic vision metrics, neural processing efficiency is another relevant endpoint. Visual information must be rapidly transmitted from the ey

Support the show

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/saffron-crocins-in-optic-neuroprotection-translating-retinal-evidence-to-glaucoma

Test your visual field online: https://visualfieldtest.com

Excerpt:

Saffron (Crocins) in Optic Neuroprotection: Translating Retinal Evidence to GlaucomaSaffron (the dried stigmas of Crocus sativus L.) is rich in carotenoid compounds, especially crocins (glycosides) and their aglycone crocetin. These bioactives have potent antioxidant, anti-inflammatory and bioenergetic effects on retinal cells. In animal and cell models, saffron extracts and purified crocin/crocetin protect photoreceptors, retinal pigment epithelium (RPE), and retinal ganglion cells (RGCs) from oxidative injury () (). Clinically, most saffron trials have focused on age-related macular degeneration (AMD) and diabetic retinopathy, showing improved visual function with doses around 20–30 mg/day () (). Emerging data suggest these benefits might extend to glaucoma. In one small study of primary open-angle glaucoma (POAG), 30 mg/day saffron significantly lowered intraocular pressure (IOP) by ~3 mmHg without side effects (). Mechanistically, saffron’s anti-inflammatory and mitochondrial-support actions – such as dampening pro‐inflammatory cytokines and preserving cellular ATP – likely underlie these effects. Recent longevity research even shows crocetin can boost tissue energy metabolism and extend median lifespan in aged mice (). Below we review the preclinical evidence of saffron’s retinal neuroprotection and perfusion effects, discuss how these might apply to glaucoma (including potential impacts on RNFL thinning and visual fields), and cover dosing and safety considerations.Preclinical Evidence in Retinal ModelsAntioxidant neuroprotection. In vitro and animal studies consistently find that crocin and crocetin guard retinal cells against oxidative stress. For example, in vitro, crocin (0.1–1 µM) prevented H₂O₂-induced death of RGC-5 cells by lowering ROS, preserving mitochondrial membrane potential (ΔΨm) and activating NF-κB (). Crocin increased anti-apoptotic Bcl-2 and decreased pro-apoptotic Bax and cytochrome c, blocking the mitochondrial apoptosis cascade (). Likewise, in vitro crocetin protected cultured human RPE cells from tert-butyl hydroperoxide injury by preventing ATP loss, maintaining nuclear integrity, and triggering a rapid ERK1/2 survival signal (). In effect, crocetin preserved the cells’ energy production pathways (mitochondrial respiration and glycolysis) under oxidative stress (). These findings show saffron metabolites directly bolster the bioenergetic health of retinal cells.Animal studies echo these effects. In a rat model of retinal ischemia–reperfusion injury, crocin supplements reduced oxidative markers and caspase-3 levels, preserving retinal thickness (). In mice exposed to intense light (a photoreceptor “light damage” model), oral saffron or crocetin also prevented photoreceptor apoptosis and preserved visual responses () (). Moreover, saffron-fed animals showed less lipid peroxidation and higher antioxidant enzyme activity in the retina (), reflecting its free-radical scavenging. Notably, some studies suggest crocin boosts retinal blood flow after ischemia (), which could improve oxygen and nutrient delivery (though blood-flow data come mainly from animal models). Together, these data indicate that saffron’s neuroprotective effects in the retina involve both direct antioxidant action and preservation of mitochondrial ATP production () ().Anti-inflammatory effects. Chronic inflammation is implicated in glaucoma and other re

Support the show